BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 36916098)

  • 1. Platin desensitizations in thoracic malignancies and risk factors for breakthrough reactions.
    Buhari GK; Kalkan İK; Ateş H; Bahçecioğlu SN; Demir Ş; Yeşilkaya S; Solak GTV; Aksu K; Erkekol FÖ
    Allergol Immunopathol (Madr); 2023; 51(2):130-136. PubMed ID: 36916098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rapid drug desensitization with platin-based chemotherapy: Analysis of risk factors for breakthrough reactions.
    Gorgulu Akin B; Erkoc M; Korkmaz ET; Ozdel Ozturk B; Colak S; Ozalp Ates FS; Bavbek S
    World Allergy Organ J; 2022 Jan; 15(1):100619. PubMed ID: 34992710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Breakthrough reactions during rapid drug desensitization: Clinical outcome and risk factors.
    Kang Y; Kwon OY; Jung H; Kang M; An J; Lee JH; Won HK; Song WJ; Kwon HS; Cho YS; Moon HB; Kim TB
    Ann Allergy Asthma Immunol; 2019 Jul; 123(1):48-56.e1. PubMed ID: 31108181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new non-dilution rapid desensitization protocol successfully applied to all-grade platinum hypersensitivity.
    Chung SJ; Kang SY; Kang RY; Kim YC; Lee KH; Kim TY; Han SW; Kang HR
    Cancer Chemother Pharmacol; 2018 Nov; 82(5):777-785. PubMed ID: 30105458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outpatient rapid 4-step desensitization for gynecologic oncology patients with mild to low-risk, moderate hypersensitivity reactions to carboplatin/cisplatin.
    Li Q; Cohn D; Waller A; Backes F; Copeland L; Fowler J; Salani R; O'Malley D
    Gynecol Oncol; 2014 Oct; 135(1):90-4. PubMed ID: 25110329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oxaliplatin hypersensitivity: evaluation, implications of skin testing, and desensitization.
    Wong JT; Ling M; Patil S; Banerji A; Long A
    J Allergy Clin Immunol Pract; 2014; 2(1):40-5. PubMed ID: 24565767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapid desensitization to antineoplastic drugs in an outpatient immunoallergology clinic: Outcomes and risk factors.
    Caiado J; Brás R; Paulino M; Costa L; Castells M
    Ann Allergy Asthma Immunol; 2020 Sep; 125(3):325-333.e1. PubMed ID: 32353405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk stratification for desensitization of patients with carboplatin hypersensitivity: clinical presentation and management.
    Hesterberg PE; Banerji A; Oren E; Penson RT; Krasner CN; Seiden MV; Wong JT
    J Allergy Clin Immunol; 2009 Jun; 123(6):1262-7.e1. PubMed ID: 19501233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outpatient desensitization of patients with moderate (high-risk) to severe platinum hypersensitivity reactions.
    Vetter MH; Khan A; Backes FJ; Bixel K; Cohn DE; Copeland LJ; Fowler JM; Salani R; Li Q; O'Malley DM
    Gynecol Oncol; 2019 Feb; 152(2):316-321. PubMed ID: 30503265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of Breakthrough Reactions in 1,143 Desensitization Procedures in a Single Tertiary Hospital Using a One-Bag Desensitization Protocol.
    Kim HH; Seo J; Ahn YH; Kim H; Yoon JE; Suh JH; Kang DY; Lee SY; Kang HR
    Front Allergy; 2022; 3():786822. PubMed ID: 35386661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carboplatin hypersensitivity: does introduction of skin test and desensitization reliably predict and avoid the problem? A prospective single-center study.
    Gomez R; Harter P; Lück HJ; Traut A; Kommoss S; Kandel M; du Bois A
    Int J Gynecol Cancer; 2009 Oct; 19(7):1284-7. PubMed ID: 19823066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk-stratification protocol for carboplatin and oxaliplatin hypersensitivity: repeat skin testing to identify drug allergy.
    Wang AL; Patil SU; Long AA; Banerji A
    Ann Allergy Asthma Immunol; 2015 Nov; 115(5):422-8. PubMed ID: 26298407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Platinum desensitization in patients with carboplatin hypersensitivity: A single-institution retrospective study.
    Altwerger G; Gressel GM; English DP; Nelson WK; Carusillo N; Silasi DA; Azodi M; Santin A; Schwartz PE; Ratner ES
    Gynecol Oncol; 2017 Jan; 144(1):77-82. PubMed ID: 27789084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A protocol for risk stratification of patients with carboplatin-induced hypersensitivity reactions.
    Patil SU; Long AA; Ling M; Wilson MT; Hesterberg P; Wong JT; Banerji A
    J Allergy Clin Immunol; 2012 Feb; 129(2):443-7. PubMed ID: 22099941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rechallenges without desensitization following platinum-based chemotherapy reactions.
    Young FD; Aung S; Tang M; Anstey KM; Lee MC; Alfaro E; Cinar P; Ho H; Otani IM
    J Oncol Pharm Pract; 2024 Apr; 30(3):572-575. PubMed ID: 38347725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk stratification and skin testing to guide re-exposure in taxane-induced hypersensitivity reactions.
    Picard M; Pur L; Caiado J; Giavina-Bianchi P; Galvão VR; Berlin ST; Campos SM; Matulonis UA; Castells MC
    J Allergy Clin Immunol; 2016 Apr; 137(4):1154-1164.e12. PubMed ID: 26725998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carboplatin hypersensitivity: a 6-h 12-step protocol effective in 35 desensitizations in patients with gynecological malignancies and mast cell/IgE-mediated reactions.
    Lee CW; Matulonis UA; Castells MC
    Gynecol Oncol; 2004 Nov; 95(2):370-6. PubMed ID: 15491759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential presentation of hypersensitivity reactions to carboplatin and oxaliplatin: Phenotypes, endotypes, and management with desensitization.
    Jimenez-Rodriguez TW; de Las Vecillas L; Labella M; Lynch DM; Besz KM; Marquis K; Burgos A; Soriano Gomis V; Lozano I; Antón RAM; de la Calle FM; González Delgado MP; Gutiérrez A; Montenegro E; Rodríguez F; Fernández Sánchez FJ; Castells M
    Allergy; 2024 Mar; 79(3):679-689. PubMed ID: 37916741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carboplatin-, oxaliplatin-, and cisplatin-specific IgE: cross-reactivity and value in the diagnosis of carboplatin and oxaliplatin allergy.
    Caiado J; Venemalm L; Pereira-Santos MC; Costa L; Barbosa MP; Castells M
    J Allergy Clin Immunol Pract; 2013; 1(5):494-500. PubMed ID: 24565621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Skin Testing in the Evaluation and Management of Carboplatin-Related Hypersensitivity Reactions.
    Lax T; Long A; Banerji A
    J Allergy Clin Immunol Pract; 2015; 3(6):856-62. PubMed ID: 26432514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.